🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9 results for “Biktarvy” Clear

  1. Biktarvy 50 mg/200 mg/25 mg film-coated tablets, PTM ISL/LEN, ISLATRAVIR/LENACAPAVIR, ISLATRAVIR/LENACAPAVIR, PTM Biktarvy

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  2. Dovato 50 mg/300 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets

    ViiV Healthcare Pty Ltd

    Human immunodeficiency virus (HIV)

    phase 3 small molecule active

    1 trial

  3. GS-1720, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-4182

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  4. GS-4182, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-1720

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  5. PTM 300 mg tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, PTM 75/50 mg FDC tablets, PTM 50/200/25 mg FDC tablets, Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS

    Gilead Sciences Pty Limited

    HIV-1 infection

    phase 3 small molecule active

    1 trial

  6. Placebo to doravirine/ islatravir, MK-8591A, Placebo to bictegravir/ emtricitabine/ tenofovir alafenamide, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  7. Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  8. Biktarvy 50 mg/200 mg/25 mg film-coated tablets

    Gilead Sciences Pty Limited

    HIV-1 infection

    approved small molecule active

    1 trial

  9. Biktarvy 50 mg/200 mg/25 mg film-coated tablets, Descovy 200 mg/25 mg film-coated tablets, Delstrigo 100 mg/300 mg/245 mg film-coated tablets, Pifeltro 100 mg film-coated tablets

    MEDA Pharma GmbH & Co. KG

    Human Immunodeficiency Virus

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources